Fibromyalgia and Vagus Nerve Connection: Pain & Symptoms Research Guide Released

via Press Release Distribution Service
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Nuropod has released a new guide exploring the connection between fibromyalgia and the vagus nerve, examining how the nervous system processes pain and why noninvasive vagus nerve stimulation is attracting growing research interest.

-- Nuropod has released a new guide examining the connection between the vagus nerve and fibromyalgia, including how pain signals are processed and why researchers are studying vagus nerve stimulation in relation to symptoms such as widespread pain and fatigue.

More information is available at https://nuropod.com/blogs/articles/vagus-nerve-and-fibromyalgia-pain-symptoms-connection

Fibromyalgia affects approximately 4 million adults in the United States, or around 2% of the adult population, the Centers for Disease Control and Prevention (CDC) reports. The condition can involve chronic widespread pain, fatigue, sleep disturbances, and cognitive difficulties, creating challenges that extend beyond physical discomfort alone.

The new guide explores these symptoms before examining why the vagus nerve has become an area of research interest. It explains that fibromyalgia is associated with changes in how the nervous system processes pain signals, rather than necessarily indicating tissue damage in the areas where pain is felt. The vagus nerve connects the brain with organs including the heart, lungs, and gut and contributes to autonomic regulation.

The guide also examines research involving Parasym's proprietary AVNT™ technology. Across studies involving different populations, the company reports an average 38% reduction in widespread pain and a 48% reduction in fatigue.

Nuropod uses the same proprietary AVNT waveform in a wearable device that delivers noninvasive vagus nerve stimulation through an earpiece attached to the tragus. The company describes typical sessions of around 30 minutes, once or twice daily, allowing users to incorporate the device into activities such as reading, working, or relaxing at home.

Parasym says its research program includes more than 60 completed clinical studies, 100+ ongoing studies, and collaborations with over 150 research institutions, supported by more than 10 years of research and development. Nuropod is intended for use alongside existing care rather than as a replacement for treatments recommended by healthcare professionals.

To learn more about Nuropod's vagus nerve stimulation technology and the research behind it, visit https://nuropod.com

Disclaimer: Research referenced in this article was conducted using Parasym’s neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as guaranteed individual outcomes. Nuropod is classified by the FDA as a non-significant risk device and is not intended to diagnose, treat, cure, or prevent any disease.

Contact Info:
Name: PR Team
Email: Send Email
Organization: Nuropod by Parasym
Address: 2108 N Street, Sacramento, California 95816, United States
Website: https://nuropod.com/

Source: PressCable

Release ID: 89210080

In case of identifying any problems, concerns, or inaccuracies in the content shared in this press release, or if a press release needs to be taken down, we urge you to notify us immediately by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your concerns and take swift action within 8 hours to rectify any issues identified or assist with the removal process. We are committed to delivering high-quality content and ensuring accuracy for our valued readers.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article